The main risk factors for diabetes include genetic predisposition and non-genetic factors such as obesity, unhealthy diet, sedentary lifestyle, and increasing age. Additionally, high blood pressure and cholesterol levels significantly contribute to the risk of developing diabetes and its complications.
An estimated 537 million adults aged 20–79 years were living with diabetes in 2021, which is projected to rise to 783 million by 2045.
Approximately 1 in 10 adults worldwide currently has diabetes, with a large proportion of cases remaining undiagnosed.
Diabetes caused an estimated 6.7 million deaths globally in 2021, representing one death every 5 seconds.
About 1 in 2 adults with diabetes remain undiagnosed, putting them at higher risk for severe complications like heart disease, kidney failure, and blindness.
GluSure is a revolutionary, first-of-its-kind point-of-care (POC) device that integrates artificial intelligence (AI) and advanced biochemical and physiological screening into a unified system for diabetes diagnosis and monitoring. Unlike existing POC devices, GluSure offers a comprehensive approach that goes beyond simple glucose monitoring, incorporating predictive and prognostic insights for better disease management.
According to our market research, the biosensors market for POC applications held the largest market share in 2021. POC applications in diabetes management include glucose monitoring, ketone tracking, and HbA1c analysis, among others. The growing prevalence of diabetes, coupled with technological advancements in POC devices, presents a significant growth opportunity.
The unique diagnostic and prognostic capabilities of GluSure create new market avenues for healthcare providers, diagnostic centers, and hospital chains. With diabetes affecting millions globally and the diabetes care devices market projected to surpass $42.4 billion, this device has the potential to disrupt and redefine at-home diabetes care, supporting early intervention and better disease management.
Providing top-notch services for all your needs.
Working with the best industry leaders.
Expanding our services across the globe.
Dedicated support for all your queries.
Our startup is dedicated to designing advanced biosensor devices that provide cutting-edge technological solutions for disease and disorder diagnosis at the home scale, empowering end users (patients) to monitor their health independently. Our primary goal is to develop an innovative biosensor for diabetes screening, a condition with a profound impact on the global population.
Our Sri aksha siddhi biochemicals Private Limited specialise in the development of ground breaking medical devices. Our team combines cutting edge technology with antibody engineering, Nanotechnology methodologies to create solutions that are not only innovative but also clinically effective and User-friendly. Our extensive experience in medical device Design ensures that we deliver the products that meet the regorous standards of the health care industry. Our approach is patient-centric and collaborative.
Partner
Partner
C - 17, 1st floor, I Hub Building, AMTZ Campus, Pragati Maidan, Visakhapatnam, Andhra Pradesh - 530031, INDIA.
+91-9346589448
akshayasiddipvtltd@gmail.com